Metreleptin for treating lipodystrophy

or staff training is not expected to be needed to introduce metreleptin in England. 4.33 The committee noted that the population for which metreleptin is indicated includes children and young people. It discussed the need to balance the importance of improving the lives of children and their families with fairness to people of all ages. It noted the principles that guide the development of NICE guidance and standards. This emphasises the importance of considering the distribution of health resources fairly within society as a whole, and factors other than relative costs and benefits alone. The committee acknowledged and considered the nature of the population as part of its decision making. Other factors 4.34 The committee discussed the nature of the condition and to what extent the severity of lipodystrophy was comparable to other ultra-rare conditions. It understood that hunger was a particular aspect of the condition which caused substantial impact on quality of life for people with lipodystrophy and was likely to be associated with other comorbidities. 4.35 It also noted that response to metreleptin is heterogenous between people with generalised lipodystrophy and partial lipodystrophy. Evidence showed that metreleptin was associated with greater benefits in people with generalised lipodystrophy and
